Bill > A2436

Introduced Session

This bill would direct the Cannabis Regulatory Commission to adopt regulations concerning labeling, marketing, and sale of cannabidiol and products containing cannabidiol, and would prohibit the sale of cannabidiol to minors. The bill would require the Cannabis Regulatory Commission, in consultation with the Department of Agriculture and the Department of Health, to adopt rules and regulations concerning the labeling, marketing, and sale of cannabidiol and products containing cannabidiol, including products intended to be ingested, applied topically, inhaled, or consumed in any form. The rules and regulations would include (1) health and safety standards for cannabidiol and products containing cannabidiol including permitted uses of cannabidiol, standardized single use amounts for cannabidiol, limits on potency, and maximum single use amount; (2) labeling and packaging standards for cannabidiol and products containing cannabidiol including single use amount, the total number of single use amounts in a package, and a statement regarding the total amount of cannabidiol contained in the product and in each serving; and (3) advertising requirements for cannabidiol and products containing cannabidiol, including a prohibition on the advertising products to minors or in ways that may risk health and safety, and limits on the health claims that may be advertised in conjunction with cannabidiol to allow only those recognized by the commission. Any rule or regulation adopted by the commission would be based upon the best available scientific data. Any regulation related to health, safety, dosage, or therapeutic claims would be valid if: (1) the underlying information has been clearly demonstrated through scientifically valid testing according to generally accepted principles;(2) a body considered to be authoritative by the Department of Health has formally endorsed the regulation or underlying information; or (3) an agency of the State or federal government has formally required the regulation or endorsed the underlying information. The bill would prohibit the sale of cannabidiol and products containing cannabidiol to minors, and would establish a penalty of $250 for the first violation; $500 for the second violation; and $1,000 for the third and each subsequent violation. Any violations of the rules and regulations established by the Cannabis Regulatory Commission concerning the labeling, marketing, and sale of cannabidiol and products containing cannabidiol would be subject to a civil penalty of $1,000 for the first offense and up to $2,000 for the second and each subsequent offense. The bill would not limit any privileges or rights of a registered qualifying patient, designated caregiver, institutional caregiver, or alternative treatment center as provided in the "Jake Honig Compassionate Use Medical Cannabis Act." The bill would also not apply to a product containing cannabidiol that is licensed or approved by the federal Food and Drug Administration under the "Federal Food, Drug, and Cosmetic Act," and used in an approved manner. The bill would amend the "New Jersey Hemp Farming Act," P.L.2019, c.238 (4:28-6 et al.) to ensure that the rules and regulations adopted by the Cannabis Regulatory Commission would not conflict with the rules and regulations adopted by the Department of Agriculture to regulate the cultivation, handling, processing, transport, and sale of hemp and hemp products.

AI Summary

Committee Categories

Annette Quijano (D)*, 

Introduced, Referred to Assembly Oversight, Reform and Federal Relations Committee (on 01/09/2024)

Official Document